Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Medtronic
Merck
McKinsey
Johnson and Johnson

Last Updated: August 15, 2022

Investigational Drug Information for ASP2151


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for ASP2151?

ASP2151 is an investigational drug.

There have been 13 clinical trials for ASP2151. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2013.

The most common disease conditions in clinical trials are Herpes Zoster, Herpes Simplex, and Herpes Genitalis. The leading clinical trial sponsors are Maruho Europe Limited, Astellas Pharma Inc, and Maruho Co., Ltd.

There are six US patents protecting this investigational drug and sixty-seven international patents.

Recent Clinical Trials for ASP2151
TitleSponsorPhase
Drug-Drug Interaction Study: ASP2151 and MidazolamMaruho Europe LimitedPhase 1
Drug-Drug Interaction Study: ASP2151 and BupropionMaruho Europe LimitedPhase 1
Drug-Drug Interaction Study: ASP2151 and MontelukastMaruho Europe LimitedPhase 1

See all ASP2151 clinical trials

Clinical Trial Summary for ASP2151

Top disease conditions for ASP2151
Top clinical trial sponsors for ASP2151

See all ASP2151 clinical trials

US Patents for ASP2151

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ASP2151 See Plans and Pricing Viral prophylaxis treatment methods and pre-exposure prophylaxis kits ELIAN LLC (Monrovia, CA) See Plans and Pricing
ASP2151 See Plans and Pricing Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form Metriopharm AG (Zurich, CH) See Plans and Pricing
ASP2151 See Plans and Pricing Methods and compositions for treating herpes Genocea Biosciences, Inc. (Cambridge, MA) See Plans and Pricing
ASP2151 See Plans and Pricing Agents for the treatment of retroviral infectious diseases IMMUNOLOGIK GMBH (Trockenborn-Wolfersdorf, DE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ASP2151

Drugname Country Document Number Estimated Expiration Related US Patent
ASP2151 Australia AU2015287994 2034-07-07 See Plans and Pricing
ASP2151 Australia AU2020203896 2034-07-07 See Plans and Pricing
ASP2151 Brazil BR112017000285 2034-07-07 See Plans and Pricing
ASP2151 Canada CA2954526 2034-07-07 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Medtronic
Merck
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.